DK0988863T4 - Stabile komplekser af tungtoplöselige forbindelser - Google Patents
Stabile komplekser af tungtoplöselige forbindelserInfo
- Publication number
- DK0988863T4 DK0988863T4 DK99117908T DK99117908T DK0988863T4 DK 0988863 T4 DK0988863 T4 DK 0988863T4 DK 99117908 T DK99117908 T DK 99117908T DK 99117908 T DK99117908 T DK 99117908T DK 0988863 T4 DK0988863 T4 DK 0988863T4
- Authority
- DK
- Denmark
- Prior art keywords
- soluble compounds
- stable complexes
- heavily soluble
- heavily
- complexes
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10133698P | 1998-09-22 | 1998-09-22 | |
US13653199P | 1999-05-28 | 1999-05-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
DK0988863T3 DK0988863T3 (da) | 2004-08-30 |
DK0988863T4 true DK0988863T4 (da) | 2009-06-08 |
Family
ID=26798138
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK99117908T DK0988863T4 (da) | 1998-09-22 | 1999-09-13 | Stabile komplekser af tungtoplöselige forbindelser |
Country Status (32)
Country | Link |
---|---|
US (1) | US6350786B1 (cs) |
EP (1) | EP0988863B2 (cs) |
JP (5) | JP2000095708A (cs) |
KR (1) | KR100362019B1 (cs) |
CN (1) | CN1201821C (cs) |
AR (2) | AR022096A1 (cs) |
AT (1) | ATE265232T1 (cs) |
AU (1) | AU770745B2 (cs) |
BR (1) | BR9904283A (cs) |
CA (1) | CA2282906C (cs) |
CO (1) | CO5140077A1 (cs) |
CZ (1) | CZ300215B6 (cs) |
DE (1) | DE69916733T3 (cs) |
DK (1) | DK0988863T4 (cs) |
ES (1) | ES2218918T5 (cs) |
HR (1) | HRP990287B1 (cs) |
HU (1) | HU228341B1 (cs) |
ID (1) | ID24034A (cs) |
IL (1) | IL131957A (cs) |
MA (1) | MA26692A1 (cs) |
MY (1) | MY124377A (cs) |
NO (1) | NO326928B1 (cs) |
NZ (1) | NZ337884A (cs) |
PE (1) | PE20001049A1 (cs) |
PL (1) | PL202757B1 (cs) |
PT (1) | PT988863E (cs) |
RS (1) | RS50193B (cs) |
RU (1) | RU2240827C2 (cs) |
SG (1) | SG97131A1 (cs) |
SI (1) | SI0988863T2 (cs) |
TR (1) | TR199902324A3 (cs) |
TW (1) | TWI234465B (cs) |
Families Citing this family (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1027886B1 (en) | 1999-02-10 | 2008-07-09 | Pfizer Products Inc. | Pharmaceutical solid dispersions |
US6440959B1 (en) * | 1999-04-21 | 2002-08-27 | Hoffman-La Roche Inc. | Pyrazolobenzodiazepines |
PE20010659A1 (es) * | 1999-10-01 | 2001-06-20 | Hoffmann La Roche | Derivados de las pirimidin-2,4,6-trionas como inhibidores de metaloproteasas |
US6313143B1 (en) * | 1999-12-16 | 2001-11-06 | Hoffmann-La Roche Inc. | Substituted pyrroles |
ES2257407T3 (es) * | 2000-05-16 | 2006-08-01 | Ortho-Mcneil Pharmaceutical, Inc. | Procedimiento para recubrir dispositivos medicos usando dioxido de carbono supercritico. |
US6469179B1 (en) | 2000-10-03 | 2002-10-22 | Hoffmann-La Roche Inc. | Amorphous form of cell cycle inhibitor having improved solubility and bioavailability |
US6482847B2 (en) | 2000-10-03 | 2002-11-19 | Hoffmann-La Roche Inc. | Amorphous form of cell cycle inhibitor having improved solubility and bioavailability |
US9700866B2 (en) | 2000-12-22 | 2017-07-11 | Baxter International Inc. | Surfactant systems for delivery of organic compounds |
US6951656B2 (en) | 2000-12-22 | 2005-10-04 | Baxter International Inc. | Microprecipitation method for preparing submicron suspensions |
US7037528B2 (en) | 2000-12-22 | 2006-05-02 | Baxter International Inc. | Microprecipitation method for preparing submicron suspensions |
US8067032B2 (en) | 2000-12-22 | 2011-11-29 | Baxter International Inc. | Method for preparing submicron particles of antineoplastic agents |
US6884436B2 (en) | 2000-12-22 | 2005-04-26 | Baxter International Inc. | Method for preparing submicron particle suspensions |
US7193084B2 (en) | 2000-12-22 | 2007-03-20 | Baxter International Inc. | Polymorphic form of itraconazole |
US20050048126A1 (en) | 2000-12-22 | 2005-03-03 | Barrett Rabinow | Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug |
US6977085B2 (en) | 2000-12-22 | 2005-12-20 | Baxter International Inc. | Method for preparing submicron suspensions with polymorph control |
US6548531B2 (en) | 2001-02-09 | 2003-04-15 | Hoffmann-La Roche Inc. | Method for cancer therapy |
US6716845B2 (en) | 2001-03-30 | 2004-04-06 | Hoffmann-La Roche Inc. | Barbituric acid derivatives |
WO2003013478A2 (en) * | 2001-05-30 | 2003-02-20 | Csir | Method of encapsulating an active substance |
US20030044514A1 (en) * | 2001-06-13 | 2003-03-06 | Richard Robert E. | Using supercritical fluids to infuse therapeutic on a medical device |
WO2002102373A1 (en) * | 2001-06-15 | 2002-12-27 | F. Hoffmann-La Roche Ag | Method for administration of cancer therapeutic |
EA200301250A1 (ru) | 2001-06-22 | 2004-06-24 | Пфайзер Продактс Инк. | Фармацевтические композиции, содержащие слаборастворимые и/или чувствительные к кислотам лекарственные средства и нейтрализованные кислотные полимеры |
WO2003000235A1 (en) | 2001-06-22 | 2003-01-03 | Pfizer Products Inc. | Pharmaceutical compositions of dispersions of drugs and neutral polymers |
US20060003012A9 (en) | 2001-09-26 | 2006-01-05 | Sean Brynjelsen | Preparation of submicron solid particle suspensions by sonication of multiphase systems |
AU2002337692B2 (en) | 2001-09-26 | 2007-09-13 | Baxter International Inc. | Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal |
US7112340B2 (en) | 2001-10-19 | 2006-09-26 | Baxter International Inc. | Compositions of and method for preparing stable particles in a frozen aqueous matrix |
US20030139373A1 (en) * | 2001-11-20 | 2003-07-24 | Breimer Lars Holger | Method for cancer therapy |
RS61604A (en) | 2002-02-01 | 2006-10-27 | Pfizer Products Inc. | Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus |
WO2004014342A1 (en) | 2002-08-12 | 2004-02-19 | Pfizer Products Inc. | Pharmaceutical compositions of semi-ordered drugs and polymers |
DE10351087A1 (de) * | 2003-10-31 | 2005-05-25 | Bayer Technology Services Gmbh | Feste Wirkstoff-Formulierung |
EP3216449A1 (en) * | 2003-11-14 | 2017-09-13 | EA Pharma Co., Ltd. | Oral administration preparation of phenylalanine derivatives |
KR101118930B1 (ko) * | 2003-11-14 | 2012-03-14 | 아지노모토 가부시키가이샤 | 페닐알라닌 유도체의 고체 분산체 또는 고체 분산체 의약제제 |
EP1735007A2 (en) * | 2004-04-01 | 2006-12-27 | F.Hoffmann-La Roche Ag | Cyclodextrin inclusion complexes of pyrimidine-2,4,6-triones |
AR049915A1 (es) * | 2004-06-14 | 2006-09-13 | Anacor Pharmaceuticals Inc | Compuestos con contenido de boro y metodos de uso de los mismos |
WO2006062980A2 (en) * | 2004-12-07 | 2006-06-15 | Nektar Therapeutics | Stable non-crystalline formulation comprising tiagabine |
CN101115469A (zh) * | 2004-12-28 | 2008-01-30 | 卫材R&D管理有限公司 | 速崩片及其制造方法 |
US8604055B2 (en) | 2004-12-31 | 2013-12-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
CA2605214C (en) | 2004-12-31 | 2016-07-12 | Reddy Us Therapeutics, Inc. | Benzylamine derivatives as cetp inhibitors |
WO2006081497A2 (en) * | 2005-01-27 | 2006-08-03 | Corium International, Inc. | Hydrophilic biocompatible adhesive formulations and uses |
EP1690528A1 (de) * | 2005-02-11 | 2006-08-16 | Abbott GmbH & Co. KG | Herstellung von Dosierungsformen mit einer festen Dispersion eines mikrokristallinen Wirkstoffs |
CA2608952A1 (en) * | 2005-05-19 | 2006-11-23 | Dwayne Thomas Friesen | Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor |
EP1767194A1 (de) * | 2005-06-09 | 2007-03-28 | Helm AG | Verfahren zur Herstellung von Adsorbaten des Drospirenons |
SI1893612T1 (sl) * | 2005-06-22 | 2012-03-30 | Plexxikon Inc | Pirolo b piridin derivati kot protein kinazni inhibitorji |
US20080031944A1 (en) * | 2006-08-04 | 2008-02-07 | Cima Labs Inc. | Stabilization of lorazepam |
US20100173921A1 (en) * | 2006-08-10 | 2010-07-08 | Cipla Limited | Antiretroviral Solid Oral Composition |
US20080107725A1 (en) * | 2006-10-13 | 2008-05-08 | Albano Antonio A | Pharmaceutical Solid Dosage Forms Comprising Amorphous Compounds Micro-Embedded in Ionic Water-Insoluble Polymers |
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
PE20081581A1 (es) * | 2006-12-21 | 2008-11-12 | Plexxikon Inc | COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA |
WO2008079909A1 (en) * | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
US20080221047A1 (en) * | 2006-12-27 | 2008-09-11 | Astellas Pharma Inc., | Aminoakyl methacrylate copolymer E for maintaining solubility of poorly-soluble drug |
CA2686756A1 (en) * | 2007-05-11 | 2008-11-20 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions for poorly soluble drugs |
US8722736B2 (en) | 2007-05-22 | 2014-05-13 | Baxter International Inc. | Multi-dose concentrate esmolol with benzyl alcohol |
US8426467B2 (en) | 2007-05-22 | 2013-04-23 | Baxter International Inc. | Colored esmolol concentrate |
EP1997479A1 (en) * | 2007-05-31 | 2008-12-03 | Helm AG | Stabilized amorphous candesartan cilexetil compositions for oral administration |
SG183036A1 (en) | 2007-07-17 | 2012-08-30 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
US20100222311A1 (en) * | 2007-10-19 | 2010-09-02 | Purdue Research Foundation | Solid formulations of crystalline compounds |
US8632805B2 (en) * | 2008-06-20 | 2014-01-21 | Mutual Pharmaceutical Company, Inc. | Controlled-release formulations, method of manufacture, and use thereof |
US7794750B2 (en) * | 2008-06-20 | 2010-09-14 | Mutual Pharmaceutical Company, Inc. | Controlled-release formulations, method of manufacture, and use thereof |
WO2010044842A1 (en) * | 2008-10-16 | 2010-04-22 | University Of Tennessee Research Foundation | Tamper resistant oral dosage forms containing an embolizing agent |
KR20100073454A (ko) * | 2008-12-23 | 2010-07-01 | 국립암센터 | 트란스글루타미나제 억제제로 사용되는 신규한 피라졸로디아제핀계 화합물, 이의 제조방법 및 이를 포함하는 조성물 |
PL2414356T3 (pl) * | 2009-04-03 | 2016-02-29 | Hoffmann La Roche | Kompozycje {3-[5-(4-chlorofenylo)-1H-pirolo[2,3-b]pirydyno-3-karbonylo]-2,4-difluorofenylo}-amidu kwasu propano-1-sulfonowego i ich zastosowania |
US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
NZ629615A (en) | 2009-11-06 | 2016-01-29 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
JPWO2011152297A1 (ja) * | 2010-05-31 | 2013-08-01 | アステラス製薬株式会社 | トリアゾール化合物の固体分散体 |
ES2696023T3 (es) | 2011-02-07 | 2019-01-11 | Plexxikon Inc | Compuestos y métodos para la modulación de quinasas e indicaciones para ello |
MX2013008476A (es) | 2011-02-17 | 2013-08-12 | Hoffmann La Roche | Proceso para cristalizacion controlada de un ingrediente farmaceutico activo a partir del estado liquido superenfriado por extrusion de fusion en caliente. |
TWI558702B (zh) | 2011-02-21 | 2016-11-21 | 普雷辛肯公司 | 醫藥活性物質的固態形式 |
HUE044043T2 (hu) | 2011-06-20 | 2019-09-30 | H Lundbeck As | Deuterizált 1-piperazino-3-fenil-indánok skizofrénia kezelésére |
US9199967B2 (en) | 2011-08-18 | 2015-12-01 | Dr. Reddy's Laboratories Ltd. | Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors |
WO2013037396A1 (en) * | 2011-09-12 | 2013-03-21 | Bioneer A/S | Solution of polymer in api for a solid dosage form |
IN2014CN02290A (cs) | 2011-09-27 | 2015-06-19 | Reddys Lab Ltd Dr | |
SG11201401459YA (en) | 2011-10-14 | 2014-07-30 | Array Biopharma Inc | Solid dispersions of a erb2 (her2) inhibitor |
PT2827900T (pt) | 2012-03-23 | 2018-06-14 | Array Biopharma Inc | Dispersões sólidas amorfas para utilização no tratamento de cancro cerebral |
US20140128431A1 (en) | 2012-04-03 | 2014-05-08 | Hoffmann-Laroche Inc. | Pharmaceutical composition with improved bioavailability, safety and tolerability |
EP2649989B1 (en) | 2012-04-13 | 2017-10-18 | King Saud University | Method for preparing a solid dispersion, solid dispersion obtained thereby and use thereof |
US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
JO3339B1 (ar) * | 2012-09-11 | 2019-03-13 | Shanghai Inst Pharmaceutical Ind | شكل مستقر غير متبلور من الأغوميلاتين وعملية تحضيره والتركيبات الدوائية التي تحتوي عليه |
AU2013346501B2 (en) | 2012-11-19 | 2017-07-13 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical compositions of CETP inhibitors |
CA2895534C (en) * | 2012-12-20 | 2019-10-22 | Kashiv Pharma, Llc | Orally disintegrating tablet formulation for enhanced bioavailability |
MX372668B (es) | 2013-01-22 | 2020-04-23 | Hoffmann La Roche | Composicion farmaceutica que comprende un compuesto ácido 4-{[(2r, 3s, 4r, 5s)-4-(4-cloro-2-fluoro-fenil)-3-(3-cloro-2-2-fluoro-fenil)-4-ciano-5-(2,2-dimetil-propil)-pirrolidin-2-carbonil]-amino}-3-metoxi-benzoico con biodisponibilidad mejorada. |
TWI615157B (zh) | 2013-02-06 | 2018-02-21 | 大塚製藥股份有限公司 | 包括不定形西洛他唑的固體分散劑 |
US20160213575A1 (en) * | 2013-09-11 | 2016-07-28 | 3M Innovative Properties Company | Coating compositions, dental structures thereof and methods for generating contrast |
CA2928772A1 (en) * | 2013-12-05 | 2015-06-11 | Alrise Biosystems Gmbh | Process for the production of drug formulations for oral administration |
PT107846B (pt) * | 2014-08-01 | 2019-03-22 | Hovione Farm S A | Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada |
WO2016193779A1 (en) * | 2015-05-29 | 2016-12-08 | Sun Pharmaceutical Industries Limited | Oral pharmaceutical composition of isotretinoin |
DK3447056T3 (da) * | 2016-12-13 | 2025-06-30 | Transthera Sciences Nanjing Inc | Multikinasehæmmerforbindelse, krystalform og anvendelse deraf |
BR112019022280A2 (pt) | 2017-04-28 | 2020-05-19 | Seattle Genetics Inc | tratamento de cânceres de her2 positivo |
KR102082775B1 (ko) * | 2017-05-02 | 2020-02-28 | 주식회사 삼양바이오팜 | 수용해도 및 생체이용율이 개선된 조성물 |
RU2725879C2 (ru) * | 2018-07-26 | 2020-07-07 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Казанский Государственный медицинский университет" Министерства здравоохранения Российской Федерации | Интерполимерный носитель для пероральных систем контролируемой доставки активных фармацевтических ингредиентов |
EP3891134A1 (en) | 2018-12-03 | 2021-10-13 | H. Lundbeck A/S | Prodrugs of 4-((1r,3s)-6-chloro-3-phenyl-2,3-dihydro-1h-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1/r,3s)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1h-inden-1-yl)-2,2-dimethy-1-(methyl-d3)piperazine |
CA3168667A1 (en) | 2020-01-24 | 2021-07-29 | Nanocopoeia, Llc | Amorphous solid dispersions of dasatinib and uses thereof |
AU2021212258A1 (en) | 2020-01-31 | 2022-09-29 | Flex Pharma, Llc | Amorphous nilotinib microparticles and uses thereof |
JP7705715B2 (ja) | 2020-03-03 | 2025-07-10 | デクセリアルズ株式会社 | 画像表示装置の製造方法 |
WO2021222739A1 (en) | 2020-04-30 | 2021-11-04 | Nanocopoeia, Llc | Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib |
US11980619B2 (en) | 2021-07-28 | 2024-05-14 | Nanocopoeia, Llc | Pharmaceutical compositions and crushable tablets including amorphous solid dispersions of dasatinib and uses |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS51118816A (en) * | 1975-04-08 | 1976-10-19 | Meiji Seika Kaisha Ltd | A process for stabilizing non-crystalloidal solid |
US4344934A (en) * | 1978-11-20 | 1982-08-17 | American Home Products Corporation | Therapeutic compositions with enhanced bioavailability |
KR870004967A (ko) * | 1985-11-27 | 1987-06-02 | 헤르비그 폰 모르체 | 무정형 벤즈 이미다졸 유도체 |
GB8608080D0 (en) * | 1986-04-02 | 1986-05-08 | Fujisawa Pharmaceutical Co | Solid dispersion composition |
NZ227850A (en) * | 1988-02-10 | 1991-11-26 | Hoffmann La Roche | Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders |
JP2528706B2 (ja) † | 1988-05-30 | 1996-08-28 | ゼリア新薬工業株式会社 | ジヒドロピリジン化合物の製剤組成物 |
USRE36736E (en) | 1989-02-06 | 2000-06-13 | Hoffman-La Roche Inc. | Substituted pyrroles |
JPH0729926B2 (ja) † | 1989-07-25 | 1995-04-05 | 大塚製薬株式会社 | 易吸収性製剤用組成物 |
US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
AU1537292A (en) † | 1991-04-16 | 1992-11-17 | Nippon Shinyaku Co. Ltd. | Method of manufacturing solid dispersion |
US5281420A (en) | 1992-05-19 | 1994-01-25 | The Procter & Gamble Company | Solid dispersion compositions of tebufelone |
TW493991B (en) | 1995-05-08 | 2002-07-11 | Novartis Ag | Pharmaceutical composition for oral administration of active agent having low water solubility and process for preparation of the same |
GB9511220D0 (en) † | 1995-06-02 | 1995-07-26 | Glaxo Group Ltd | Solid dispersions |
BE1009856A5 (fr) * | 1995-07-14 | 1997-10-07 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule. |
DE69628276T2 (de) * | 1995-07-26 | 2004-04-08 | Kyowa Hakko Kogyo Co., Ltd. | Zubereitung von xanthinderivaten als feste dispersion |
WO1997008950A1 (en) † | 1995-09-07 | 1997-03-13 | Fuisz Technologies, Ltd. | System for rendering substantially non-dissoluble bio-affecting agents bio-available |
DE19548624A1 (de) | 1995-12-23 | 1997-06-26 | Boehringer Mannheim Gmbh | Neue Barbitursäure-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
JPH09208459A (ja) * | 1996-02-07 | 1997-08-12 | Eisai Co Ltd | 溶解性を改良した製剤 |
NZ332234A (en) | 1996-03-12 | 2000-06-23 | Pg Txl Company Lp | Water soluble paclitaxel prodrugs formed by conjugating paclitaxel or docetaxel with a polyglutamic acid polymer and use for treating cancer |
EP0954288B1 (en) * | 1996-06-28 | 2004-08-11 | Schering Corporation | Solid solution of an antifungal agent with enhanced bioavailability |
PE91598A1 (es) | 1996-07-29 | 1998-12-24 | Hoffmann La Roche | Pirroles sustituidos |
US6229011B1 (en) | 1997-08-22 | 2001-05-08 | Hoffman-La Roche Inc. | N-aroylphenylalanine derivative VCAM-1 inhibitors |
PT1064279E (pt) | 1998-03-17 | 2003-10-31 | Hoffmann La Roche | Bisindolilmaleimidas substituidas para a inibicao da proliferacao celular |
-
1999
- 1999-09-07 US US09/391,060 patent/US6350786B1/en not_active Expired - Lifetime
- 1999-09-13 ES ES99117908T patent/ES2218918T5/es not_active Expired - Lifetime
- 1999-09-13 DK DK99117908T patent/DK0988863T4/da active
- 1999-09-13 EP EP99117908A patent/EP0988863B2/en not_active Expired - Lifetime
- 1999-09-13 DE DE69916733T patent/DE69916733T3/de not_active Expired - Lifetime
- 1999-09-13 SI SI9930573T patent/SI0988863T2/sl unknown
- 1999-09-13 AT AT99117908T patent/ATE265232T1/de active
- 1999-09-13 PT PT99117908T patent/PT988863E/pt unknown
- 1999-09-16 IL IL13195799A patent/IL131957A/xx not_active IP Right Cessation
- 1999-09-17 CZ CZ0330499A patent/CZ300215B6/cs not_active IP Right Cessation
- 1999-09-17 SG SG9904570A patent/SG97131A1/en unknown
- 1999-09-17 NZ NZ337884A patent/NZ337884A/xx not_active IP Right Cessation
- 1999-09-17 CO CO99059117A patent/CO5140077A1/es unknown
- 1999-09-17 PE PE1999000947A patent/PE20001049A1/es not_active IP Right Cessation
- 1999-09-20 HR HR990287 patent/HRP990287B1/xx not_active IP Right Cessation
- 1999-09-20 AR ARP990104725A patent/AR022096A1/es not_active Application Discontinuation
- 1999-09-20 ID IDP990878D patent/ID24034A/id unknown
- 1999-09-20 CA CA2282906A patent/CA2282906C/en not_active Expired - Lifetime
- 1999-09-20 TW TW088116184A patent/TWI234465B/zh not_active IP Right Cessation
- 1999-09-20 HU HU9903189A patent/HU228341B1/hu unknown
- 1999-09-20 AU AU48807/99A patent/AU770745B2/en not_active Expired
- 1999-09-20 MY MYPI99004065A patent/MY124377A/en unknown
- 1999-09-21 BR BR9904283-5A patent/BR9904283A/pt not_active Application Discontinuation
- 1999-09-21 MA MA25778A patent/MA26692A1/fr unknown
- 1999-09-21 JP JP11267142A patent/JP2000095708A/ja not_active Withdrawn
- 1999-09-21 NO NO19994583A patent/NO326928B1/no not_active IP Right Cessation
- 1999-09-21 RU RU99120377/15A patent/RU2240827C2/ru active
- 1999-09-21 RS YUP-473/99A patent/RS50193B/sr unknown
- 1999-09-21 TR TR1999/02324A patent/TR199902324A3/tr unknown
- 1999-09-21 CN CNB991194063A patent/CN1201821C/zh not_active Expired - Lifetime
- 1999-09-22 PL PL335592A patent/PL202757B1/pl unknown
- 1999-09-22 KR KR1019990041130A patent/KR100362019B1/ko not_active Expired - Lifetime
-
2007
- 2007-06-06 JP JP2007150911A patent/JP2007224048A/ja active Pending
-
2011
- 2011-04-13 AR ARP110101253A patent/AR080892A2/es not_active Application Discontinuation
-
2012
- 2012-10-18 JP JP2012230446A patent/JP6253135B2/ja not_active Expired - Lifetime
-
2015
- 2015-07-16 JP JP2015141952A patent/JP2015187170A/ja active Pending
-
2016
- 2016-08-31 JP JP2016169245A patent/JP6534979B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0988863T4 (da) | Stabile komplekser af tungtoplöselige forbindelser | |
DE60025198D1 (de) | Stabile biozidale zusammensetzung | |
DE59902428D1 (de) | Foggingfreies Klebeband | |
ATE311118T1 (de) | Stabile salatsossen | |
DK1124961T3 (da) | Trombopoietiske forbindelser | |
DK0900088T3 (da) | Inklusionskomplekser af arylheterocykliske salte | |
DE69829864D1 (de) | Stabile feste blockförmige waschmittelzusammensetzung | |
ATE248849T1 (de) | Verbrückte metallkomplexe | |
ATE229954T1 (de) | Betacarbolinverbindungen | |
ID28266A (id) | Senyawa-senyawa amidin | |
NO20011745L (no) | Forbindelser | |
IS5843A (is) | Fenýl janþín (yanthine) afleiður | |
NO20005006L (no) | Kalsilytiske forbindelser | |
IS5772A (is) | Þalazín (phthalazine) afleiður af fosfódíesterasa4 lötum | |
DK1087992T3 (da) | Antithrombotiske forbindelser | |
DE60007044D1 (de) | Stabile biozide Zusammensetzungen | |
NO20006662D0 (no) | Fluorfenylresin-forbindelser | |
DK1155050T3 (da) | Fremstilling af polyolefin | |
DE59911099D1 (de) | Stabile mitoxantron-lösungen | |
DE69903701D1 (de) | Stabile 3-Isothiazolonzusammensetzungen | |
DE69910409D1 (de) | Disaccharide-derivate | |
FI980902A7 (fi) | Levosimendaanin stabiileja koostumuksia | |
DK1088010T3 (da) | Fremstilling af polyolefiner | |
DE69813426D1 (de) | Stabile Bleichmittelzusammensetzungen | |
ATE228522T1 (de) | Dinukleare fluoroaryl-aluminium-alkylkomplexe |